Nash And Nafld An Issue Of Clinics In Liver Disease

Obesity has devastating effects on a patient's overall health, with specific negative effects on organ systems, long-term. The hepatologist must often manage diseases of the liver and pancreas as a result of obesity. This issue will provide a current update on the diagnosis, treatment, and management of NAFLD and NASH. Dr. Bernstein has assembled the top leaders in the field to provide timely clinical reviews. Articles are devoted to the following topics: Clinical and economic burden of NAFLD/NASH; NAFLD/NASH in children and its implications; Natural history of NAFLD/NASH; Diagnosis and evaluation of NAFLD/NASH; Radiological imaging in NAFLD/NASH; The use of liver biopsy in NAFLD: When to biopsy and in whom; Pathophysiology of NAFLD/NASH; Risk factors for the development of NAFLD/NASH including genetics; Role of intestinal microbes in NAFLD/NASH; NAFLD/NASH and the metabolic syndrome; NAFLD/NASH and lipid and insulin resistance; NAFLD/NASH and cardiac disease; Current treatment of NAFLD/NASH; Emerging treatment of NAFLD/NASH; NAFLD/NASH and HCC and NAFLD/NASH and liver transplantation. Readers will have a clear understanding of how to manage outcomes for these patients.

Dr. Sanyal's expertise as Chairman of the Division of Hepatology at Virginia Commonwealth University and the breadth of his published articles in hepatology make him the perfect person to compile state-of-the-art reviews on the topic of NASH/fatty liver. The articles in this issue address the following topics: The Genetic Epidemiology of Nonalcoholic Fatty Liver Disease; Relevance of Liver Histology to Predict Clinically Meaningful Outcomes in NASH; Mechanisms of Simple Hepatic Steatosis; Cellular and Molecular Basis for Phenotype of Steatohepatitis; Mechanisms of Disease Progression in NASH: New Paradigms; Can NASH Be Diagnosed, Graded and Staged Non-Invasively?; Is NAFLD in Children the Same Disease as in Adults?; The Cardiovascular Link to NAFLD: A Critical Analysis; Impact of Behavioral Disturbances and Their Treatment on Obesity and NAFLD; and Management of NASH.

Although effective treatments for Non-alcoholic Steatohepatitis (NASH) are yet to be developed, several potentially promising treatment approaches are under investigation. This issue of Clinics in Liver Diseases presents the views of several internationally renowned NAFLD experts on the most up to date epidemiology, natural history, diagnosis, pathogenesis, and treatment of NAFLD. Additionally, this issue presents recent work on to the importance of NAFLD in children, as well as in the individuals who undergo weight reduction surgery. Experts discuss the role of new technologies, such as genomics and proteomics, in understanding NAFLD and developing new biomarkers, including fibrosis markers. Presents recent work on to the importance of NAFLD in children, as well as in the individuals who undergo weight reduction surgery.

Obesity has devastating effects on a patient's overall health, with specific negative effects on organ systems, long-term. The hepatologist must often manage diseases of the liver and pancreas as a result of obesity. This issue will provide a current update on the diagnosis, treatment, and management of NAFLD and NASH. Dr. Bernstein has assembled the top leaders in the field to procide timely clinical reviews. Articles are devoted to the following topics: Clinical and economic burden of NAFLD/NASH; NAFLD/NASH in children and its implications; Natural history of NAFLD/NASH; Diagnosis and evaluation of NAFLD/NASH; Radiological imaging in NAFLD/NASH; The use of liver biopsy in NAFLD: When to biopsy and in whom; Pathophysiology of NAFLD/NASH; Risk factors for the development of NAFLD/NASH including genetics; Role of intestinal microbes in NAFLD/NASH; NAFLD/NASH and the metabolic syndrome; NAFLD/NASH and lipid and insulin resistance; NAFLD/NASH and cardiac disease; Current treatment of NAFLD/NASH; Emerging treatment of NAFLD/NASH; NAFLD/NASH and HCC and NAFLD/NASH and liver transplantation. Readers will have a clear understanding of how to manage outcomes for these patients.

In this issue, guest editors bring their considerable expertise to this important topic. Contains 20 practice-oriented topics, including metabolic syndrome associated with NASH; genetic markers and comorbidities predisposing to NASH and progressive liver disease; the role of bariatric surgery and endobariatric surgery in NASH; future treatment options and regimens for NAFLD; and more. Provides in-depth clinical reviews on non-alcoholic steatohepatitis, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Together with Consulting Editor Dr. Alan Buchman, Drs. Arun J. Sanyal and Mohammad Siddiqui have put together a comprehensive issue devoted to fatty liver disease for the gastroenterologist. Expert authors have contributed clinical review articles on the following topics: Burden of disease due to NAFLD; Genetic risk factors and disease modifiers of NASH; How to identify the patient with NASH who will progress to cirrhosis; Similarities and Differences between cirrhosis due to NASH versus other etiologies; Impications of NASH as the etiology of end stage liver disease prior to and after liver transplantation; Why do lifestyle recommendations fail in most patients; Rational nutritional therapeutics for NAFLD; Recruitment and retention strategies in long-term trials for NASH; Managing extrahepatic comorbidities in NAFLD; The current status of noninvasive tools for the assessment of NAFLD; and Pharmacological Treatment strategies for NASH. Readers will come away with the information they need to improve outcomes in patients with fatty liver disease.

Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD.

Fatty Liver Diseases: NASH and Related Disorders is an unusual book: it combines a practical approach for students and physicians concerned with the problem with a clear overview on the causative mechanisms. It appeals to doctors and other health care workers who encounter this problem, as well as to pathologists and investigators interested in the field of liver disease. It will improve your diagnostic acumen for people with abnormal liver tests, advance your knowledge about this important subject and help with your specialist or undergraduate exams, and management of a common disorder.